Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;24(11):1358-1373.
doi: 10.2174/1566524023666230801160452.

Aminoglycosides: Single- or Multiple-daily Dosing? An Updated Qualitative Systematic Review of Randomized Trials on Toxicity and Efficacy

Iman Karimzadeh  1 , Meghdad Abdollahpour-Alitappeh  2 , Shokouh Ghaffari  3 , Motahareh Mahi-Birjand  4 , Amin Barkhordari  5 , Effat Alemzadeh  3
Affiliations

Aminoglycosides: Single- or Multiple-daily Dosing? An Updated Qualitative Systematic Review of Randomized Trials on Toxicity and Efficacy

Iman Karimzadeh et al. Curr Mol Med. 2024.

Abstract

Introduction: Aminoglycosides are among the first-choice antibiotics for routine clinical use. However, dose-limiting factors such as ototoxicity and nephrotoxicity are considered as serious complications of aminoglycosides.

Objective: In this systematic review, the main goal was to investigate the efficacy and incidence of nephrotoxicity and ototoxicity of once-daily dosing (ODD) and multiple daily dosing (MDD) regimens of aminoglycosides through available randomized controlled trials (RCTs).

Methods: We performed a literature-based research in relevant databases, including EMBASE, MEDLINE, and SCOPUS published between 1987 and 2023 using the keywords "aminoglycosides", "pharmacokinetics", "ODD", "MDD", "once daily", "multiple daily", "dosing regimen", "nephrotoxicity", "ototoxicity", "efficacy", "safety", and "toxicity". As so told, the results of this article were limited to papers available in English. Our initial search yielded 1124 results. After a review of the titles and abstracts of the articles, 803 articles were excluded from this study because they did not address the toxicity and effectiveness of ODD versus MDD of aminoglycosides. A total number of 20 studies on gentamicin, tobramycin, netilmicin, and amikacin met the inclusion criteria for the efficacy of aminoglycosides and their role in ototoxicity and nephrotoxicity were included in this review. Studies recruited different age classes, and the age of relevant cohorts varied from only a few days to more than 70 years.

Results: The most common clinical condition in the included studies was cystic fibrosis.

Conclusion: In most studies, there were no significant differences between the two regimens regarding ototoxicity. In addition, the ODD regimens were safer than MDD concerning nephrotoxicity.

Keywords: Aminoglycosides; nephrotoxicity; ototoxicity; pharmacokinetics; safety; toxicity..

PubMed Disclaimer

References

    1. Elshahawi SI; Shaaban KA; Kharel MK; Thorson JSJCSR; A comprehensive review of glycosylated bacterial natural products. Chem Soc Rev 2015,44((21)),7591-697 - DOI
    1. Dezanet C.; Kempf J.; Mingeot-Leclercq M.P.; Décout J.L.; Amphiphilic aminoglycosides as medicinal agents. Int J Mol Sci 2020,21(19),7411 - DOI - PubMed
    1. Bryskier A.; American Society of Microbiology 2005,13-38
    1. Serio A.W.; Magalhães M.L.; Blanchard J.S.; Connolly L.E.; Aminoglycosides: Mechanisms of Action and Resistance Antimicrobial Drug Resistance. Antimicrob Agents Chemother 2000,44(12),3249-3256 - DOI
    1. Bowers D.R.; Schilling A.N.; Tam V.H.; Antibiotic Pharmacodynamics 2016,199-220

Publication types

MeSH terms